Refine
Has Fulltext
- yes (83)
Is part of the Bibliography
- yes (83)
Year of publication
Document Type
- Journal article (69)
- Conference Proceeding (8)
- Preprint (6)
Language
- English (83) (remove)
Keywords
- PET (24)
- Positronen-Emissions-Tomografie (20)
- positron emission tomography (15)
- prostate cancer (13)
- theranostics (13)
- PRRT (8)
- neuroendocrine tumor (8)
- CXCR4 (7)
- PET/CT (7)
- PSMA (7)
- radioligand therapy (7)
- SPECT (6)
- SSTR (6)
- 18F-FDG (5)
- RADS (5)
- molecular imaging (5)
- prostate-specific membrane antigen (5)
- PSMA-RADS (4)
- inflammation (4)
- somatostatin receptor (4)
- sympathetic nervous system (4)
- 18F-DCFPyL (3)
- 18F-LMI1195 (3)
- DaTscan (3)
- NET (3)
- Prostate Cancer (3)
- ageing (3)
- machine learning (3)
- norepinephrine transporter (3)
- peptide receptor radionuclide therapy (3)
- reporting and data system (3)
- vandetanib (3)
- 11C-HED (2)
- 123I-mIBG (2)
- 123I-metaiodobenzylguanidine (2)
- 18F-FDS (2)
- C-X-C motif chemokine receptor 4 (2)
- DOTATOC (2)
- Ioflupane (2)
- MAG3 (2)
- MIBG (2)
- MRI (2)
- Myokarditis (2)
- Neuroendocrine Tumor (2)
- PSMA I&T (2)
- PSMA-PET (2)
- Parkinson (2)
- Parkinson Disease (2)
- Parkinson-Krankheit (2)
- Positron Emission Tomography (2)
- SSTR-RADS (2)
- SUV (2)
- Stammzelle (2)
- TKI (2)
- Virchow Node (2)
- [177Lu]-DOTATATE/-DOTATOC (2)
- [68Ga] (2)
- [68Ga]PentixaFor (2)
- cardiac innervation imaging (2)
- cardiac nerve (2)
- cardiomyocytes (2)
- chemokine receptor (2)
- diabetes (2)
- endoradiotherapy (2)
- fatty acid (2)
- heart failure (2)
- hiPSC-CM (2)
- induced pluripotent stem cells (2)
- kidney (2)
- medullary thyroid carcinoma (2)
- molecular medicine (2)
- multiple myeloma (2)
- myocardial sympathetic innervation imaging (2)
- myocarditis (2)
- personalized medicine (2)
- personalized treatment (2)
- precision medicine (2)
- prostate-specific membrane antigen (PSMA) (2)
- solid tumors (2)
- somatostatin receptor (SSTR) (2)
- stem cell therapy (2)
- tracer (2)
- tumor heterogeneity (2)
- tyrosine kinase inhibitor (2)
- 11C-Hydroxyephedrine (1)
- 11C-hydroxyephedrine (1)
- 123I-Ioflupane (1)
- 177Lu (1)
- 177Lu-DOTATATE (1)
- 177Lu-DOTATOC (1)
- 18F-DCFPL (1)
- 18F-flurpiridaz (1)
- 18FFBnTP (1)
- 2- deoxy-2-(18F)fluoro-D-glucose (1)
- 2-deoxy-2-(18F)fluoro-D-glucose (1)
- 2-deoxy-2-18F-fluoro-D-sorbitol (1)
- 68Ga-DOTANOC (1)
- 68Ga-DOTATATE (1)
- 68Ga-DOTATATE/-TOC (1)
- 68Ga-DOTATOC (1)
- 99mTc-DTPA (1)
- <sup>18</sup>F-FDG (1)
- <sup>68</sup>Ga-Pentixafor (1)
- AI (1)
- Antidepressants (1)
- Arginine (1)
- COVID-19 (1)
- CTCAE (1)
- CXCR4-targeting (1)
- Cardiovascular diseases (1)
- DCGAN (1)
- ECG (1)
- FV45 (1)
- GAN (1)
- GCA (1)
- GI (1)
- Ganglia (1)
- Gastrointestinal (1)
- Gleason score (1)
- Glomerular filtration (1)
- HFmrEF (1)
- Heart failure (1)
- Herz (1)
- Hyperkalaemia (1)
- ICD (1)
- Imaging pitfalls (1)
- Journal of Nuclear Cardiology (1)
- Lysine (1)
- MDD (1)
- MI-RADS (1)
- MPI (1)
- Magnetresonanztomografie (1)
- Medullärer Schilddrüsenkrebs (1)
- Metaiodobenzylguanidine (1)
- Myocardial-perfusion SPECT (1)
- NEC (1)
- Neuroendocrine (1)
- Nierenfunktionsstörung (1)
- Oncology (1)
- PMR (1)
- PROMISE (1)
- PSA (1)
- PSA response (1)
- PSMA-617 (1)
- PSMA-RADS-3A (1)
- PSMA-RADS-3B (1)
- PSMA-TV (1)
- PSMA-targeted PET (1)
- PSMA‐617 (1)
- Pancreas (1)
- Parkinsonism (1)
- Parkinson’s disease (1)
- Pentixafor (1)
- Pitfall (1)
- Positron-Emission Tomography (1)
- Positronenemissionstomografie (1)
- Prostata (1)
- RLT (1)
- Radiofluorine (1)
- Radionuclide Therapy (1)
- Radiotracer (1)
- SARS-CoV-2 (1)
- SPECT Scanner (1)
- SPECT/CT (1)
- SSTR-PET (1)
- Single-Photon-Emissions-Computertomographie (1)
- Sodium-Glucose Cotransporters (SGLTs) (1)
- Standardisierung (1)
- T-shaped π-π stacking (1)
- T-shaped π–π stacking (1)
- TIMP-1 (1)
- Tracer (1)
- ZDF rats (1)
- [11C]-Choline PET/CT (1)
- [11C]-Methionine (1)
- [177Lu]/[90Y]PentixaTher (1)
- [177Lu]Lu-PSMA I&T (1)
- [177Lu]PentixaTher (1)
- [18F]FDG PET/CT (1)
- [68Ga]DOTATOC (1)
- [68Ga]Pentixafor (1)
- [90Y]PentixaTher (1)
- [99mTc]-Sestamibi scan (1)
- [\(^{68}\)Ga]Ga-FAPI (1)
- [\(^{68}\)Ga]Pentixafor (1)
- \(^{177}\)Lu (1)
- \(^{18}\)F (1)
- \(^{18}\)F-DCFPyL PET/CT (1)
- \(^{18}\)F-FDG (1)
- \(^{18}\)F-PSMA-1007 (1)
- \(^{18}\)F-fluorodeoxyglucose (1)
- \(^{68}\)Ga (1)
- activation (1)
- adrenocortical carcinoma (1)
- amino acids (1)
- angiogenesis (1)
- angiotensin II type 1 receptor (1)
- antidepressant (1)
- antidepressants (1)
- arrhythmia (1)
- artificial intelligence (1)
- autonomic nervous system (1)
- biomarkers (1)
- blood flow (1)
- cardiac (1)
- cardiac neurohormonal system (1)
- cardiac sympathetic nerve system (1)
- cardiac sympathetic nervous system (1)
- cardioprotective potential (1)
- clinical studies (1)
- combination (1)
- computational biology and bioinformatics (1)
- coronary artery disease (1)
- depression (1)
- diabetic cardiomyopathy (1)
- editorial (1)
- ejection fraction (1)
- endocrinology (1)
- epithelial-cells (1)
- fibroblast activation protein (1)
- flare phenomenon (1)
- focused surgical approach (1)
- giant cell arteritis (1)
- glial fate modulation (1)
- glomerular filtration rate (1)
- heart (1)
- heart failure with mid-range ejection fraction (1)
- hematotoxicity (1)
- hydroxyephedrine (1)
- hyperkalemia (1)
- immune infiltration (1)
- implants (1)
- interobserver (1)
- interreader (1)
- kidney function (1)
- kinase (1)
- late response (1)
- left-ventricular function (1)
- lung-cancer (1)
- mIBG (1)
- mRNA (1)
- magnetic resonance imaging (1)
- major depressive disorder (1)
- matched pair (1)
- medicine (1)
- medium-sized animals (1)
- meningioma (1)
- mesenchymal stem cells (1)
- miRNA (1)
- mouse models (1)
- moycardial sympathetic innervation (1)
- myelin (1)
- myocardial nerve (1)
- myocardial perfusion imaging (1)
- nephrology (1)
- nephrotoxicity (1)
- neural stem cells (1)
- neuroblastoma (1)
- neuroendocrine neoplasia (1)
- neuroendocrine neoplasms (NEN) (1)
- neuroendocrine tumors (NET) (1)
- neurology (1)
- nonhuman primates (1)
- nuclear cardiology (1)
- obstructive pulmonary-disease (1)
- oligodendroglia (1)
- overall survival (1)
- pancreas (1)
- papillary thyroid carcinoma (PTC) (1)
- parathyroid adenoma (1)
- pathway (1)
- performance (1)
- phaeochromocytoma (1)
- polymyalgia rheumatica (1)
- preclinical research (1)
- prediction (1)
- primary hyperparathyroidism (1)
- prostate-specific antigen (1)
- protein (1)
- quantification (1)
- radioiodine (1)
- radiotracer (1)
- radiotracer kinetics (1)
- rats (1)
- renal (1)
- renal failure (1)
- renal function (1)
- renal imaging (1)
- renal scintigraphy (1)
- renin-angiotensin system (1)
- reporting and data systems (1)
- retrospective studies (1)
- sarcoidosis (1)
- secretome (1)
- selpercatinib (1)
- sigma-1 receptor-directed molecular imaging (1)
- single photon emission computed tomography: sympathetic nerve (1)
- somatic mutations (1)
- spinal cord (1)
- spinal cord injury (1)
- spleen (1)
- split renal function (1)
- staging (1)
- standardization (1)
- standardized reporting (1)
- standardized reporting system (1)
- statin (1)
- stem cells (1)
- stem-cell research (1)
- storage vesicle turnover (1)
- stroke (1)
- structure–activity relationships (1)
- sympathetic nerve (1)
- taxane (1)
- thyroid carcinoma (TC) (1)
- transcriptome (1)
- transplantation (1)
- tumor microenvironment (1)
- unilateral ureteral obstruction (1)
- uptake (1)
- urology (1)
- valsartan (1)
- vasculature (1)
- vasculitis (1)
Institute
- Klinik und Poliklinik für Nuklearmedizin (80)
- Medizinische Klinik und Poliklinik I (12)
- Medizinische Klinik und Poliklinik II (11)
- Deutsches Zentrum für Herzinsuffizienz (DZHI) (8)
- Urologische Klinik und Poliklinik (8)
- Institut für Anatomie und Zellbiologie (4)
- Institut für Pharmazie und Lebensmittelchemie (4)
- Comprehensive Cancer Center Mainfranken (3)
- Pathologisches Institut (3)
- Institut für Klinische Biochemie und Pathobiochemie (2)
Sonstige beteiligte Institutionen
- Johns Hopkins School of Medicine (17)
- Johns Hopkins University School of Medicine (5)
- Johns Hopkins School of Medicine, Baltimore, MD, U.S. (4)
- Department of Biomedical Imaging, National Cerebral and Cardiovascular Research Center, Suita, Japan (2)
- Division of Medical Technology and Science, Department of Medical Physics and Engineering, Course of Health Science, Osaka University Graduate School of Medicine, Suita Japan (2)
- Institut for Molecular Biology and CMBI, Department of Genomics, Stem Cell Biology and Regenerative Medicine, Leopold-Franzens-University Innsbruck, Innsbruck, Austria (2)
- Johns Hopkins School of Medicine, The Russell H Morgan Department of Radiology and Radiological Science, Baltimore, MD, USA (2)
- Department of Nuclear Medicine, Kanazawa University (1)
- Hospital Augsburg, Augsburg, Germany (1)
- Johns Hopkins Medicine (1)
EU-Project number / Contract (GA) number
- 701983 (38)
Introduction: Therapeutic options in advanced medullary thyroid carcinoma (MTC) have markedly improved since the introduction of tyrosine kinase inhibitors (TKI). We
aimed to assess the role of metabolic imaging using 2-deoxy-2-(\(^{18}\)F)fluoro-D-glucose (\(^{18}\)F-FDG) positron emission tomography/computed tomography (PET/CT) shortly before and 3 months after initiation of TKI treatment.
Methods: Eighteen patients with advanced and progressive MTC scheduled for vandetanib treatment underwent baseline \(^{18}\)F-FDG PET/CT prior to and 3 months after TKI treatment initiation. During follow-up, CT scans were performed every 3 months and analyzed according to Response Evaluation Criteria In Solid Tumors (RECIST). The predictive value for estimating progression-free (PFS) and overall survival (OS) was examined by investigating \(^{18}\)F-FDG mean/maximum standardized uptake values (SUVmean/max) of the metabolically most active lesion as well as by analyzing clinical parameters (tumor marker doubling times {calcitonin, carcinoembryonic antigen (CEA)}, prior therapies, RET (rearranged during transfection) mutational status, and disease type).
Results: Within a median follow-up of 5.2 years, 9 patients experienced disease progression after a median time interval of 2.1y whereas the remainder had ongoing disease control (n=5 partial response and n=4 stable disease). Eight of the 9 patients with progressive disease died from MTC after a median of 3.5y after TKI initiation.
Pre-therapeutic SUVmean >4.0 predicted a significantly shorter PFS (PFS: 1.9y vs. 5.2y; p=0.04). Furthermore, sustained high 18F-FDG uptake at 3 months with a SUVmean>2.8 tended to portend an unfavorable prognosis with a PFS of 1.9y (vs. 3.5y; p=0.3). Prolonged CEA doubling times were significantly correlated with longer PFS (r=0.7) and OS (r=0.76, p<0.01, respectively). None of the other clinical parameters had prognostic significance.
Conclusions: Pre-therapeutic \(^{18}\)F-FDG PET/CT holds prognostic information in patients with advanced MTC scheduled for treatment with the TKI vandetanib. Low tumor metabolism of SUVmean < 4.0 prior to treatment predicts longer progression-free survival.
Background: Precise regional quantitative assessment of renal function is limited with conventional \(^{99m}\)Tc-labeled renal radiotracers. A recent study reported that the positron emission tomography (PET) radiotracer 2-deoxy-2-(\(^{18}\)F-fluorosorbitol (\(^{18}\)F-FDS) has ideal pharmacokinetics for functional renal imaging. Furthermore, (\(^{18}\)F-FDS is available via simple reduction from routinely used 2-deoxy-2-(\(^{18}\)F-fluoro-D-glucose ((\(^{18}\)F-FDG). We aimed to further investigate the potential of (\(^{18}\)F-FDS PET as a functional renal imaging agent using rat models of kidney diseases.
Methods: Two different rat models of renal impairment were investigated: Glycerol induced acute renal failure (ARF) by intramuscular administration of glycerol in hind legs and unilateral ureteral obstruction (UUO) by ligation of the left ureter. 24h after these treatments, dynamic 30 min 18F-FDS PET data were acquired using a dedicated small animal PET system. Urine 18F-FDS radioactivity 30 min after radiotracer injection was measured together with co-injected \(^{99m}\)Tc-diethylenetriaminepentaacetic acid (\(^{99m}\)Tc-DTPA) urine activity. Results: Dynamic PET imaging demonstrated rapid (\(^{18}\)F-FDS accumulation in the renal cortex and rapid radiotracer excretion via kidneys in control healthy rats. On the other hand, significantly delayed renal radiotracer uptake (continuous slow uptake) was observed in ARF rats and UUO-treated kidneys. Measured urine radiotracer concentrations of (\(^{18}\)F-FDS and \(^{99m}\)Tc-DTPA were well correlated (R=0.84, P<0.05).
Conclusions: (\(^{18}\)F-FDS PET demonstrated favorable kinetics for functional renal imaging in rat models of kidney diseases. Advantages of high spatiotemporal resolution of PET imaging and simple tracer production could potentially complement or replace conventional renal scintigraphy in select cases and significantly improve the diagnostic performance of renal functional imaging.
Background: \(^{123}\)I-metaiodobenzylguanidine (mIBG) provides independent prognostic value for risk stratification among heart failure patients, but the use of concomitant medication should not impact its quantitative information. We aimed to evaluate the four most-prescribed antidepressants currently used as a first‑line treatment for patients with major depressive disorder (MDD) and their potential on altering mIBG imaging results.
Methods: The inhibition effect of four different types of antidepressants (desipramine, escitalopram, venlafaxine and bupropion) for MDD treatment on \(^{131}\)I-mIBG uptake was assessed by in-vitro cell uptake assays using human neuroblastoma SK-N-SH cells. The half maximal inhibitory concentration (IC50) of tracer uptake was determined from dose-response curves. To evaluate the effects of IV pretreatment with desipramine (1.5 mg/kg) and escitalopram (2.5, 15 mg/kg) on mIBG cardiac uptake, in-vivo planar 123I-mIBG scans in healthy New Zealand White Rabbits were conducted. Results: The IC50 values of desipramine, escitalopram, venlafaxine and bupropion on \(^{131}\)I-mIBG cellular uptake were 11.9 nM, 7.5 μM, 4.92 μM, and 12.9 μM, respectively. At the maximum serum concentration (Cmax, as derived by previous clinical trials), the inhibition rates of 131I-mIBG uptake were 90.6 % for desipramine, 25.5 % for venlafaxine, 11.7 % for bupropion and 0.72 % for escitalopram. A low inhibition rate for escitalopram in the cell uptake study triggered investigation of an in-vivo rabbit model: with dosage considerably higher than clinical practice, the non-inhibitory effect of escitalopram was confirmed. Furthermore, pretreatment with desipramine led to a marked reduction of cardiac 123I-mIBG uptake.
Conclusions: In the present in-vitro binding assay and in-vivo rabbit study, the selective-serotonin reuptake inhibitor escitalopram had no major impact on neuronal cardiac mIBG uptake within therapeutic dose ranges, while other types of first-line antidepressants for MDD treatment led to a significant decrease. These preliminary results warrant further confirmatory clinical trials regarding the reliability of cardiac mIBG imaging, in particular, if the patient’s neuropsychiatric status would not tolerate withdrawal of a potentially norepinephrine interfering antidepressant.
Reliable standards and criteria for somatostatin receptor (SSTR) positron emission tomography (PET) are still lacking. We herein propose a structured reporting system on a 5-point scale for SSTR-PET imaging, titled SSTR-RADS version 1.0, which might serve as a standardized assessment for both diagnosis and treatment planning in neuroendocrine tumors (NET). SSTR-RADS could guide the imaging specialist in interpreting SSTR-PET scans, facilitate communication with the referring clinician so that appropriate work-up for equivocal findings is pursued, and serve as a reliable tool for patient selection for planned Peptide Receptor Radionuclide Therapy.
Brown adipose tissue (BAT) is an attractive therapeutic target to combat diabetes and obesity due to its ability to increase glucose expenditure. In a genetic rat model (ZDF fa/fa) of type-2 diabetes and obesity, we aimed to investigate glucose utilization of BAT by \(^{18}\)F-FDG PET imaging. Male Zucker diabetic fatty (ZDF) and Male Zucker lean (ZL) control rats were studied at 13 weeks. Three weeks prior to imaging, ZDF rats were randomized into a no-restriction (ZDF-ND) and a mild calorie restriction (ZDF-CR) group. Dynamic \(^{18}\)F-FDG PET using a dedicated small animal PET system was performed under hyperinsulinemic-euglycemic clamp. \(^{18}\)F-FDG PET identified intense inter-scapular BAT glucose uptake in all ZL control rats, while no focally increased \(^{18}\)F-FDG uptake was detected in all ZDF-ND rats. Mild but significant improved BAT tracer uptake was identified after calorie restriction in diabetic rats (ZDF-CR). The weight of BAT tissue and fat deposits were significantly increased in ZDF-CR and ZDF-ND rats as compared to ZL controls, while UCP-1 and mitochondrial concentrations were significantly decreased. Whitening and severely impaired insulin-stimulated glucose uptake in BAT was confirmed in a rat model of type-2 diabetes. Additionally, calorie restriction partially restored the impaired BAT glucose uptake.
Purpose: Early identification of aggressive disease could improve decision-support in pancreatic neuroendocrine tumor (pNET) patients prior to peptide receptor radionuclide therapy (PRRT). The prognostic value of intratumoral textural features (TF) determined by baseline somatostatin receptor (SSTR)-PET before PRRT was analyzed.
Procedures: 31 patients with G1/G2 pNET were enrolled (G2, n=23/31). Prior to PRRT with [\(^{177}\)Lu]DOTATATE (mean, 3.6 cycles), baseline SSTR-PET/CT was performed. By segmentation of 162 (median per patient, 5) metastases, intratumoral TF were computed. The impact of conventional PET parameters (SUV\(_{mean/max}\)), imaging-based TF as well as clinical parameters (Ki67, CgA) for prediction of both progression-free (PFS) and overall survival (OS) after PRRT was evaluated.
Results: Within a median follow-up of 3.7y, tumor progression was detected in 21 patients (median, 1.5y) and 13/31 deceased (median, 1.9y). In ROC analysis, the TF Entropy, reflecting derangement on a voxel-by-voxel level, demonstrated predictive capability for OS (cutoff=6.7, AUC=0.71, p=0.02). Of note, increasing Entropy could predict a longer survival (>6.7, OS=2.5y, 17/31), whereas less voxel-based derangement portended inferior outcome (<6.7, OS=1.9y, 14/31). These findings were supported in a G2 subanalysis (>6.9, OS=2.8y, 9/23 vs. <6.9, OS=1.9y, 14/23). Kaplan-Meier analysis revealed a significant distinction between high- and low-risk groups using Entropy (n=31, p<0.05). For those patients below the ROC-derived threshold, the relative risk of death after PRRT was 2.73 (n=31, p=0.04). Ki67 was negatively associated with PFS (p=0.002); however, SUVmean/max failed in prognostication (n.s.).
Conclusions: In contrast to conventional PET parameters, assessment of intratumoral heterogeneity demonstrated superior prognostic performance in pNET patients undergoing PRRT. This novel PET-based strategy of outcome prediction prior to PRRT might be useful for patient risk stratification.